Viral hepatitis is the leading cause of liver disease worldwide. Hepatitis C virus (HCV) is the major causative agent of non-A, non-B viral hepatitis, affecting 170 million people around the world, including approximately 4 million in the USA and 8 million in Europe and Japan. It has been estimated that HCV infection is responsible for 10000-12000 deaths annually in the USA. Although acute HCV infection is often asymptomatic, the virus establishes chronic infection in up to 85% of infected individuals. As many as 20% of these infected individuals will develop cirrhosis and 1-5% will develop liver failure and hepatocellular carcinoma.
It has been estimated that HCV infection is responsible for 10000-12000 deaths annually in the USA. Although acute HCV infection is often asymptomatic, the virus establishes chronic infection in up to 85% of infected individuals. As many as 20% of these infected individuals will develop cirrhosis and 1-5% will develop liver failure and hepatocellular carcinoma.
HCV is a member of the hepacivirus genus of Flaviviridae (Rice, 1996; Lindenbach & Rice, 2003) . It is a positive-strand RNA virus with a genome of about 10000 nucleotides containing a large open reading frame. The polyprotein translated from the open reading frame is processed into at least 10 viral proteins by a combination of host and viral proteases. These viral proteins include the structural (core, E1, E2 and p7) and the nonstructural (NS2, NS3, NS4A, NS4B, NS5A and NS5B) proteins. The N-terminal one-third of the NS3 protein functions as a serine protease and the remainder has RNA helicase activity. NS4A is a co-factor of the NS3 serine protease. Little is known about the function of either NS4B or the phosphoprotein NS5A. NS5B is the viral RNA-dependent RNA polymerase (RdRp) and is essential for viral replication.
Current standard therapy for chronic hepatitis C consists of a combination of pegylated interferon-alpha (IFNα) and ribavirin. It confers an overall sustained virological response (SVR) of around 54-56% among treated patients, but is less efficacious against infection by HCV genotype 1. The limited effectiveness and adverse side effects of the current therapy underscores the urgent need for development of more effective and HCV-specific antiviral therapeutics. Recent development of a selectable HCV replicon cell culture system has significantly accelerated the drug discovery process. In the replicon system, modified forms of HCV genome are able to replicate to high levels in human hepatoma cells (Huh-7) and stably transfected replicon cell lines are established after continuous drug selection with G418. The HCV replicon cell culture system has since been widely used as a valuable tool in the evaluation of potential anti-HCV inhibitors. In this review, we will summarize recent progress of the HCV replicon system and its use in antiviral drug discovery.
Introduction

HCV replicon cell culture system
Replicon development
In vitro cultivation of HCV has been extremely elusive, and for many years HCV antiviral discovery has been hampered by the lack of a robust cellular system for the analysis of viral replication. The development of bicistronic subgenomic RNA replicon systems for HCV has significantly advanced the pace of this effort (Lohmann et al., 1999; Blight et al., 2000) . These replicons replicate in human hepatoma Huh-7 cells and contain the viral 5′ and 3′ untranslated regions ( Figure 1A ). They use HCV and EMCV internal ribosome entry sites (IRES) to direct translation from the first and second cistron, respectively. The first cistron encodes the selectable neomycin phosphotransferase gene (neo r ); the second cistron translates the HCV non-structural proteins required for viral replication (NS2-NS5B or NS3-NS5B).
Since their initial development, the replicons have been further modified to become more suitable for studying viral RNA replication and for high-throughput compound screening (HTS) in drug discovery efforts. Replacement of the neo gene with a reporter gene such as luciferase ( Figure  1B ) allows detection of RNA replication in transiently transfected cells 48-72 h post-transfection, eliminating the need for lengthy selection procedures (Krieger et al., 2001; Lohmann et al., 2001) . Mutations can be introduced into viral genes and the effect of these mutations on replication can be assessed by comparison of the luciferase signal produced from the transfected cells.
For HTS purposes, however, replicons containing both a reporter and a selectable marker have proven most useful. In this case, the first cistron would produce a polypeptide containing a reporter such as luciferase and a selectable marker conferring antibiotic resistance, linked by a sequence (for example, ubiquitin) that mediates proteolytic cleavage between the two proteins ( Figure 1C ) (Vrolijk et al., 2003) . Another replicon variant suitable for HTS incorporates HIV Tat protein linked to, but also cleavable from, a selectable marker (Yi et al., 2002) . Upon expression, Tat activates expression of a reporter gene that is stably integrated into the host genome. Reporter genes that have been successfully incorporated into HCV replicons include luciferase, secreted alkaline phosphatase and β-lactamase (Yi et al., 2002; Murray et al., 2003; Vrolijk et al., 2003) . Mono-cistronic replicons have also been developed. They typically consist of a selectable marker with a cleavable sequence fused directly to the non-structural proteins ( Figure 1D ) (Frese et al., 2002; Bartenschlager et al., 2003) . This eliminates the need for EMCV IRES to direct translation from the second cistron, thus ensuring that inhibitors of EMCV IRES-mediated translations are not selected during compound screening. A, the structure of the HCV replicon as originally designed by Lohmann et al. (1999) . B, replacement of the selectable marker with a reporter. This construct allows more rapid detection of RNA replication in transient transfection assays. C, reporter and a selectable marker, joined by a cleavable sequence, generate a stable reporter cell line commonly used in drug discovery. D, a monocistronic replicon lacking the EMCV IRES.
3′NTR
Until recently, replication of HCV replicon has been confined to Huh-7 cells. Efficient replication also correlates with the appearance of specific adaptive mutations in replicon sequence Krieger et al., 2001; Blight et al., 2000; Guo et al., 2001) . Sequence analysis of viral RNA isolated from replicon-containing Huh-7 cells revealed conserved mutations in various nonstructural proteins. When introduced into the wild-type replicons, some of these mutations conferred a higher replication phenotype and were thus designated as adaptive mutations. Several adaptive mutations have been found in NS3 that cluster around the junction of the serine protease and RNA helicase domains and appear to be located on the surface of the protein Blight et al., 2003; Lohmann et al., 2003; Grobler et al., 2003) . Two conserved changes, K1846 and V1897, have been found in NS4B (Guo et al., 2001; Kishine et al., 2002; . Adaptive mutations have also been identified in the hyper-phosphorylation region of NS5A Blight et al., 2000) . Several of these mutations involve the serine residues that are implicated in NS5A hyperphosphorylation. Mutations of these residues resulted in a reduction in the hyperphosphorylation of NS5A, suggesting an inverted relationship between NS5A hyperphosphorylation and RNA replication in the replicon cells. In NS5B a single mutation, R2884G, has been shown to increase replication significantly (Lohmann et al., 1999; Lohmann et al., 2001) .
Some of the adaptive mutations lead to higher levels of RNA replication when occurring simultaneously. For example, NS3 adaptive mutations E1202G and T1280I, combined with the NS5A adaptive mutation S2197P, result in the highest colony formation efficiency in Con-1 1b replicon (Krieger et al., 2001; Lohmann et al., 2003) . In the H77 1a replicon, NS3 mutation P1496L and NS5A mutation S2204I appear to be the most effective combination (Blight et al., 2003) .
However, adaptive mutations that increase replicon RNA replication efficiency in cell culture may be detrimental to HCV amplification in vivo. The original Con-1 RNA that was used to generate the first replicon construct is replication-competent in chimpanzees and replicates in Huh-7 cells, albeit at very low levels. The introduction of adaptive mutations E1202G, T1280I and S2197, despite drastically improving RNA replication efficiency in Huh-7 cells, completely abolished the ability of Con-1 RNA to infect chimpanzees (Bukh et al., 2002) . Conversely, the H77 RNA that has been shown to be infectious in chimpanzees is not capable of replicating in Huh-7 cells without the presence of adaptive mutations (Kolykhalov et al., 1997; Blight et al., 2003) .
Cells
Differences in Huh-7 cells contribute to the efficiency of HCV RNA replication. Colony formation efficiency has been shown to vary with the passage number of Huh-7 cells as well as the amount of input RNA, suggesting a role for cellular factor(s) . This is in agreement with the observation that host cell proliferation is required for HCV RNA replication (Pietschmann et al., 2001) . It has also been observed that subsets of Huh-7 cells are more permissive to replicon RNA replication (Blight et al., 2002; Murray et al., 2003) . Cells treated with an agent that blocks HCV RNA replication (for example, IFN-α) can become 'cured' of the replicon. These cells are essentially a pool of cells selected for their initial ability to support establishment of RNA replication. This subpopulation of cells is apparently more permissive than naive Huh-7 cells. Furthermore, Murray et al. (2003) have shown that the efficiency with which a particular replicon RNA can replicate in a population of cells is more closely associated with the number of cells in which the replicon can be established, rather than to having a higher number of replicons per cell. Together, these results indicate that both cell culture adaptive mutations in replicon sequences as well as a sub-population of permissive cells are required for efficient replication.
HCV genotypes and host range of replicons
HCV replicons in Huh-7 cells developed for research have mainly been genotype 1b, with replicating genotype 1a replicons being established more recently (Blight et al., 2003) . Chimeric replicons containing portions of genotype 1a and 1b have also been developed and used to define interaction between the 3′ NTR and viral non-structural proteins . Recently, replicons based on genotype 2a sequences have been reported (Kato et al., 2003) . The sequence was obtained from a patient with fulminant hepatitis. This replicon was able to replicate in Huh-7 cells without adaptive mutations, despite the fact that some mutations did result in higher replication efficiencies.
Recently, HCV RNA replication has also been demonstrated in cells other than Huh-7. Genotype 1b replicons can replicate in both HeLa (human cervical carcinoma) and Hepa1-6 (mouse hepatoma) cells (Zhu et al., 2003) . HCV RNA isolated from Huh-7 cells was used to transfect a panel of cells in this study. It is likely that the high degree of heterogeneity of HCV RNA replicating in Huh-7 cells would increase the probability of replicating in other cell types. A different approach was used to establish the same 1b genotype in HEK293 cells (human kidney) (Ali et al., 2004) . In this case, Huh-7 cells harbouring HCV replicon RNA were fused to HEK293 cells. At very low frequency, colonies of 293 cells that contained the replicon could be isolated under selection. Date and colleagues have shown that their genotype 2a replicon, described above, can replicate in two hepatocyte-derived cell lines, HepG2 and IMY-N9 (Date et al., 2004) . Interestingly, the 293 cell replicon developed by Ali et al. (2004) is sensitive to poly(I):poly(C), a double-stranded RNA analogue. Replicon levels in Huh-7 cells are not sensitive to poly(I): poly(C) (Lanford et al., 2003) . This illustrates how screening for inhibitors of HCV RNA replication in only one cell type may overlook potentially useful molecules.
The establishment and availability of the HCV replicon cell culture system has significantly facilitated anti-HCV drug discovery efforts. Large collections of compounds have been screened by using the replicon assay and various promising lead candidates have been evaluated and optimized for antiviral activity. The following sections summarize inhibitors that are currently under development and their activities against HCV replicon.
HCV protease inhibitors
HCV NS3 serine protease consists of the amino-terminal 180 amino acids of the NS3 protein and the NS4A cofactor. It plays an essential role in viral replication by catalysing the proteolytic cleavages of the viral polyprotein at four junctions: NS3/NS4A, NS4A/NS4B, NS4B/ NS5A and NS5A/NS5B. This viral enzyme has been the focus of drug discovery efforts in the past decade, with significant advances made in the past few years. Several strategies have been used for the development of NS3 protease inhibitors, including blockage of NS3-NS4A interaction, interference of zinc binding and preventing the substrate binding to the active site. The third strategy seems to be the most successful approach and has yielded a number of promising drug candidates including BILN 2061 (Boehringer Ingelheim) and VX-950 (Vertex Pharmaceuticals) which are currently under clinical development. On the other hand, despite various efforts in targeting HCV NS3 RNA helicase activity, promising drug candidates inhibiting the HCV helicase function have not been identified for clinical development.
BILN 2061
BILN 2061 is a product-based, potent and non-covalent competitive inhibitor of HCV genotypes 1a and 1b NS3 serine proteases ([1], Table 1), with mean inhibitory constants (K i ) of 0.30 nM and 0.66 nM, respectively, measured in an in vitro enzymatic assay (Lamarre et al., 2003) . It is highly specific to HCV NS3 protease with no significant activity against human leukocyte elastase and human liver cathepsin B (IC 50 >30 µM), representatives of serine and cysteine proteases.
Consistent with the potent anti-NS3 protease activity in vitro, BILN 2061 showed profound effects on HCV RNA replication in the HCV subgenomic replicon cell culture (Lamarre et al., 2003) . Treatment of replicon-containing cells with BILN 2061 for 3 days resulted in a dose-dependent reduction of HCV RNA of two orders of magnitude with a mean effective concentration (EC 50 ) of 4 nM and 3 nM for the HCV replicons 1a and 1b, respectively. The mechanism of inhibition of BILN 2061 was further confirmed in HCV replicon cells by its ability to block NS3-mediated polyprotein processing. This result demonstrates that BILN 2061 can enter target cells and suppress viral RNA replication by exerting its anti-NS3 protease activity. More significantly, in a small clinical trial in patients infected with HCV genotype 1, administration of BILN 2061 resulted in an impressive reduction of HCV RNA plasma levels after a 2 day treatment, clearly establishing the proof-of-concept in humans for an HCV NS3 protease inhibitor (Lamarre et al., 2003) .
Lessons from anti-HIV therapies using nucleoside or small molecule inhibitors against viral enzymes revealed that emergence of resistant viruses is a major hurdle to achieving long-term clinical efficacy in patients. It is conceivable that this situation may also apply to HCV therapies using drugs directly targeting viral enzymes, due to the inherent low fidelity and high mutation rate of HCV RNA polymerase. With the availability of the HCV replicon system, it is now possible to use the replicon cells to identify and characterize resistance profiles of various drug candidates. This strategy has been successfully applied to BILN 2061, whose resistance mutations have been mapped to substitutions in NS3 protease at residues alanine 156 to threonine (A156T), arginine 155 to glutamine (R155Q), and aspartate 168 to valine or alanine (D168V or D168A) Lu et al., 2004) . These resistance mutations reduced replicon sensitivity to BILN 2061 in the range of 24-to >1000-fold. The resistance information generated from the replicon cell culture is expected to facilitate future design of clinical studies, monitoring appearance of drug resistance during therapy and development of more effective antiviral agents.
VX-950
VX-950 is a reversible, covalent peptidomimetic inhibitor of HCV NS3 serine protease ([2], Table 1 ). It exhibits apparent non-competitive inhibition kinetics as a result of its time-dependent tight binding properties. To achieve tight binding to the protease, the terminal group α-ketoamide of VX-950 forms a reversible covalent bonding with the catalytic serine (Ser-139) residue in NS3 protease (Perni et al., : the discovery of an inhibitor of the hepatitis C NS3-4A protease and a potential hepatitis C virus therapeutic, 54th Annual Meeting of the American Association for the Study of Liver Diseases, November 2004, Boston, USA). VX-950 has an inhibitory constant (K i ) of 3 nM against HCV genotype 1b NS3 protease (Perni et al., 2003b) . When tested against HCV Con 1 subgenomic replicon cells, VX-950 showed an effective concentration (EC 50 ) of 354 nM after 48 h treatment . At higher concentrations (>3 µM), a continuing decline of HCV replicon RNA was observed during an extended (9 day) treatment period. This continuing decline of viral RNA induced by VX-950 treatment has been attributed to the multiple-step, tight binding kinetics of this compound to the protease .
The drug-resistance mutation to VX-950 has been mapped in the HCV replicon to substitution at alanine residue 156 of NS3 to serine (A156S) . Replicon RNA containing the A156S mutation showed a 12-fold reduction in sensitivity to VX-950 . Cross-resistance properties of VX-950 and BILN 2061 were examined using the drug-resistant replicons.
Interestingly, the major BILN 2061-resistant mutations at Asp168 are fully susceptible to VX-950, and the dominant resistant mutation against VX-950 at Ala156 remains sensitive to BILN-2061, suggesting that different mechanisms exist for generating resistance to these two inhibitors. It also supports the possibility that both NS3 protease inhibitors may be used in combination for the treatment of HCV infections. VX-950 is currently in Phase I clinical trial.
In addition to BILN 2061 and VX-950, another HCV NS3 protease inhibitor, SCH6 (Schering-Plough Research Institute, Kenilworth, NJ, USA), is also in Phase I clinical trial, but no structural and activity information has been released. 
HCV NS5B polymerase inhibitors
Nucleoside inhibitors
Nucleoside-based inhibitors target the active site of the polymerase protein by mimicking its natural substrates. They bind directly to the protein and are commonly incorporated into the nascent RNA strand.
2′-C-methyl adenosine and guanosine ([3,4] , Table 2 ) display a broad-spectrum antiviral activity against a number of RNA viruses including HCV and related viruses, such as bovine viral diarrhoea virus (BVDV) . The triphosphates of the nucleoside inhibitors are incorporated into nascent RNA strands and cause chain termination . In the HCV replicon assay, 2′-C-methyl adenosine exhibits good potency with an EC 50 of 0.17 µM, while 2′-C-methyl guanosine is slightly less active with an EC 50 of 1.4 µM. Drug resistance studies using replicon-containing cells have produced mutant replicons that contain a threonine at position 282 in place of a serine (S282T). Ser-282 is located in the active site of NS5B . Several classes of modifications have been introduced into this series of inhibitors and have been characterized in the HCV replicon assay, generating valuable structure-activity relationship (SAR) information (Eldrup et al., 2004a; Eldrup et al., 2004b; . These studies have yielded additional drug candidates (for example, 7-deaza-2′-C-methyl-adenosine analogues) with improved antiviral activity and pharmacokinetic profiles ([5] , Table 2 ). NM283 (Idenix Pharmaceuticals) is an orally bioavailable valine ester prodrug of 2′-C-methyl cytidine (NM107) currently in Phase I/II clinical trials ([6] , Table 2 ) (Godofsky et al., 2004) . NM383 has been recently shown to reduce serum HCV RNA levels in both chronically infected chimpanzees and patients. The triphosphate of 2′-C-methyl cytidine (NM107) has been reported to be a chain-terminating, competitive inhibitor of NS5B RdRp of BVDV, a surrogate virus of HCV, with a Ki of 160 nM and is active against replication of BVDV in cell culture with EC 50 between 0.30 and 2.77 µM, depending on the strain of BVDV tested (Standring, NM283 has potent antiviral activity against chronic hepatitis C virus genotype 1 infection in the chimpanzee, 
Non-nucleoside inhibitors
Benzo-1,2,4-thiadiazine from GlaxoSmithKline is one of the few classes of non-nucleoside NS5B inhibitors that have been proposed as a potential binder to the highly conserved polymerase active site. A representative compound from this series has achieved good potency in both NS5B enzymatic assay (EC 50 =80 nM) and the HCV replicon assay (EC 50 =0.5 µM) (Dhanak et al., 2002) ([7] , Table 2 ) and has been shown to inhibit the initiation step of viral RNA replication . It is highly synergistic with interferon-α in the HCV replicon assay. Replicon RNA synthesis is disrupted immediately upon addition of the compound . Drug resistance studies have produced replicon clones with significantly reduced susceptibility Tomei et al., 2004) . The mutation that confers resistance to this series of compounds has been mapped to the methionine residue at 414 (M414T), which is in close proximity to the NS5B active site. A similar NS5B inhibitor, A-782759, is also being developed at Abbott Laboratories (Abbott Park, IL, USA) ([8], Table 2 Japan Tobacco is developing a series of benzimidazole carboxylic acid derivatives as allosteric NS5B inhibitors. One representative compound ([9], Table 2 ) has been extensively characterized . It exhibits an IC 50 of 0.28 µM in an NS5B RdRp assay and an EC 50 of 0.35 µM in the HCV replicon assay. Drug-resistant mutation has been mapped to proline 495 (P495) in NS5B where a change to leucine (P495L) results in resistance. P495 residue is conserved in most HCV strains, highlighting the importance of this residue for HCV replication. This also helps explain the reduced replication efficiency of the P495L substituted HCV replicon . Importantly, residue 495 is a leucine in a HCV genotype 6 strain, suggesting that natural resistance does exist to this class of inhibitors. A similar lead scaffold is also being pursued by Boehringer Ingelheim (Beaulieu et al., 2004a; Beaulieu et al., 2004b) .
Shire Biochem published a series of N, N-disubstituted phenylalanine derivatives that allosterically inhibit NS5B activity Chan et al., 2003; Wang et al., 2003) . Another series of allosteric inhibitors based on the thiophene-2-carboxylic acid scaffold has also been developed by the same company (Chan et al., 2004a; Chan et al., 2004b) . One representative compound ([10] , Table 2 ) has an IC 50 of 1.5 µM in a NS5B enzymatic assay and an EC 50 of 0.6 µM in the HCV replicon assay (Chan et al., 2004b) and has good selectivity in Huh-7 cells with a CC 50 >123 µM. The drug resistant mutations for this class of compound are L419M, M423T and M423I within NS5B (Pogam et al., In vitro 
Inhibitors of other viral proteins identified by replicon screening
Another important utility of the HCV replicon cell culture system is to identify inhibitors of viral RNA replication other than those affecting virally encoded enzymes such as NS5B polymerase, NS3 serine protease and RNA helicase. To date, the function of two HCV non-structural proteins (NS4B, NS5A) remains elusive despite the fact that they are required for viral RNA replication and are believed to be components of HCV replication complexes (Moradpour et al., 2004; Moradpour et al., 2003; Gosert et al., 2003; Egger et al., 2002; Lundin et al., 2003) . It is postulated that both NS4B and NS5A are involved in interaction with other viral proteins or cellular factors during the processes of RNA synthesis. However, direct screening of compounds targeting these proteins is not feasible as in vitro assays specifically involving these two proteins have not been established.
Nonetheless, by screening with the replicon-based assays, inhibitors of HCV RNA replication can be identified that are not limited to those only affecting viral enzymatic functions (NS3 and NS5B). When inhibitors of such characteristics (non-NS3, non-NS5B inhibitors) are identified, drug resistance studies will be employed to identify the potential molecular target for those replication inhibitors. A good example of this approach has been demonstrated in identification of a series of NS5A inhibitor by scientists at Bristol-Myers Squibb Company (WO 2004/014852 A2). In their antiviral screening using the HCV replicon assay, a series of compounds (iminothiazolidinones derivatives) that possess anti-replicon activity (EC 50 ) as low as <100 nM was identified (compounds [11] and [12], Table 3 ). These compounds are not inhibitors of NS5B polymerase or NS3 serine protease and/or RNA helicase. Interestingly, when replicon cell lines resistant to this class of inhibitors were isolated and characterized, a major resistance mutation was mapped to a tyrosine residue at position 93 in NS5A, which was changed to a histidine (Y93H) or cysteine residue (Y93C). The Y93H or Y93C substitution in NS5A, when engineered back into the wildtype replicon, rendered the replicon cells at least 50-fold more resistant to compound [12].
Another example of this approach is the identification of a small molecule that modulates HCV RNA replication in cell culture but does not directly inhibit viral enzymes (compound [13], October 2004, Heidelberg, Germany) . This compound inhibits replication of adapted HCV replicons but stimulates replication of non-adapted replicons. Drug resistant mutations for this compound are mapped to NS5A protein at residues alanine 92 (A92V), tyrosine 93 (Y93H) and arginine 157 (R157W), with each mutation by itself sufficient for conferring resistance. Interestingly, one of the mutations, Y93H, was also identified as the resistant mutation for compounds [11] and [12], suggesting that they may affect similar NS5A function.
Taken together, the above studies confirmed that small molecules can inhibit HCV RNA replication in cell culture by affecting the function of non-enzymatic viral proteins such as NS5A. They clearly exemplified the utility of using replicon-based assays to identify small molecules that target essential but not yet characterized viral functions involved in RNA replication. At the present time, HCV repliconbased assay is the only suitable assay to identify such replication inhibitors.
Concluding remarks
Development of the HCV replicon cell culture model represents one of the most significant advances in HCV basic research and antiviral discovery in recent years. For the first time, HCV RNA was observed to replicate in vitro to high levels in human hepatoma cells and efficacy of antiviral compounds targeting HCV RNA replication machinery can be readily evaluated. With the availability of replicon cell culture system, promising drug candidates can be carefully evaluated and optimized before progression into clinical development. Considering that a robust and reliable small animal model for HCV is still lacking, the replicon cell culture system is playing an even more important role in early characterization of promising drug candidates.
The replicon cell culture model, however, lacks several key steps in the virus life cycle including cell entry, uncoating, RNA packaging, virion assembly and release. These steps are conceivably attractive targets for antiviral interference. Until the establishment of an authentic cell culture system that supports the full life cycle of HCV, most therapeutic approaches and discovery efforts to suppress HCV propagation other than RNA replication will remain static. Future research should continue focusing on establishment of the in vitro cell culture model that supports all aspects of the HCV life cycle.
